Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 5: 897 - 905

DOI: https://doi.org/10.19852/j.cnki.jtcm.20221121.003

Pingxiao capsule (平消胶囊) inhibits lung metastasis of triple-negative breast cancer and sensitizes breast cancer to radiotherapy

  • Wenjuan TANG ,
  • Yu HU ,
  • Man ZHU ,
  • Mingzhi DONG ,
  • Tieming LIU ,
  • Ammar SARWAR ,
  • Yingzhuan ZHAN ,
  • Yanmin ZHANG
Expand
  • 1 School of Pharmacy, Health Science Center, Xi’an Jiaotong University, Xi’an 710061, China
    2 State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, China
    3 Xi’an C.P. Pharmaceutical Co., Ltd., Xi’an, 710043, China

Received date: 2022-05-15

  Accepted date: 2022-08-25

  Online published: 2022-11-21

Supported by

Natural Science Basic Research Plan of Shaanxi Province in China: Chloroguanil Inhibits Breast Cancer Progression by Targeting GHRH/GHRHR Pathway(2021JM-030);Project from the Basic Research Project in Shaanxi Administration of Traditional Chinese Medicine: Inhibitory Effects of Xiakucao (Spica Prunellae Vulgaris)-Maozhuacao (Radix Ranunculi Ternati) Drug Pair on Breast Cancer(JCMS028)

Fold

Abstract

OBJECTIVES: To investigate the anticancer effect of Pingxiao capsule (平消胶囊, PXC) on the treatment of breast cancer in vitro and in vivo.
METHODS: The inhibition of PXC on cell viability and proliferation was determined by cell counting kit-8, EdU assay and colony formation assay, respectively. The effect of PXC on cell apoptosis was detected by using flow cytometry. The suppression of PXC on cell migration and invasion was investigated by chamber assay. To investigate the underlying molecular mechanisms, the expression of proteins related to epithelial to mesenchymal transition (EMT) was analyzed by Western blotting in breast cancer cells and by immunohistochemistry in tumor tissues. The anticancer effect of PXC in vivo was evaluated by using MDA-MB-231 xenograft model and 4T1 metastatic breast cancer model.
RESULTS: Our results indicated that triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and MDA-MB-468 were sensitive to PXC. PXC potently inhibited the proliferation, colony formation, migration, and invasion of MDA-MB-231 and MDA-MB-468 cells in vitro. Then, in vivo MDA-MB-231 xenograft model depicted that PXC significantly reduced tumor size and weight compared with Control. 4T1 lung metastasis model showed that PXC significantly inhibited breast cancer cell spreading to lungs in mice. Mechanistically, PXC inhibited EMT process by reducing cadherin turnover in TNBC. Furthermore, PXC in combination with 8 Gy X-ray treatment obviously promoted the induction of apoptosis, and suppressed cell proliferation.
CONCLUSION: PXC could inhibit the proliferation and invasion of TNBC both in vitro and in vivo, and exerted its anti-metastatic effect by regulating cadherin turnover, Furthermore, it sensitized the TNBC cells to radiotherapy. The data supported further development of PXC as an adjuvant-therapy agent for TNBC.

Key words： triple negative breast neoplasms; anti-cancer activity; Pingxiao capsule

Cite this article

Wenjuan TANG , Yu HU , Man ZHU , Mingzhi DONG , Tieming LIU , Ammar SARWAR , Yingzhuan ZHAN , Yanmin ZHANG . Pingxiao capsule (平消胶囊) inhibits lung metastasis of triple-negative breast cancer and sensitizes breast cancer to radiotherapy[J]. Journal of Traditional Chinese Medicine, 2023 , 43(5) : 897 -905 . DOI: 10.19852/j.cnki.jtcm.20221121.003

References

1. Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 2019; 1152: 51-64.
2. Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol 2020; 65: 18-31.
3. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016; 293: 247-69.
4. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020; 22: 61.
5. Chaudhary LN. Early stage triple negative breast cancer: management and future directions. Semin Oncol 2020; 47: 201-8.
6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 2007; 109: 1721-8.
7. Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 2013; 13: 31-9.
8. Cheng RYS, Patel NL, Back T, et al. Studying triple negative breast cancer using orthotopic breast cancer model. J Vis Exp 2020; 157: e60316.
9. Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 2019; 9: 176-98.
10. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 2018; 8: 1483-507.
11. Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese Medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med 2019; 8: 1958-75.
12. Liao YH, Li CI, Lin CC, Lin JG, Chiang JH, Li TC. Traditional Chinese Medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017; 143: 2425-35.
13. Wang Y, Zhang Q, Chen Y, et al. Antitumor effects of immunity-enhancing Traditional Chinese Medicine. Biomed Pharmacother 2020; 121: 109570.
14. Wang JX, Wang ZY, Mei QB. Research progress of the Pingxiao capsule in the treatment of breast diseases. World Clinical Drugs 2016; 37: 144-8.
15. Tang TL, Sun Y, Li YH, et al. Pharmacodynamics of Pingxiao capsule in rat model of mammary gland hyperplasia. Central South Pharmacy 2020; 18: 1837-41.
16. Zhang Y, Han B, Huang H, Liu Y, Surgery DO. Effect of Xiaozhong Sanjie decoction combined with Pingxiao capsule on inflammatory factors and immune factors in patients with non-lactation mastitis. Medical Recapitulate 2020; 26: 1856-9.
17. Li HJ. Clinical study on Pingxiao capsules combined with oxaliplatin in treatment of esophageal cancer. Xian Dai Yao Wu Yu Lin Chuang 2019; 34: 3421-5.
18. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017; 168: 670-91.
19. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92.
20. Anasamy T, Chee CF, Kiew LV, Chung LY. In vivo antitumour properties of tribenzyltin carboxylates in a 4T1 murine metastatic mammary tumour model: enhanced efficacy by PLGA nanoparticles. Eur J Pharm Sci 2020; 142: 105140.
21. Citrin DE. Recent developments in radiotherapy. N Engl J Med 2017; 377: 1065-75.
22. Bradley JA, Mendenhall NP. Novel radiotherapy techniques for breast cancer. Annu Rev Med 2018; 69: 277-88.
Options
Outlines

/

〈 〉